Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
OBIZUR susoctocog alfa (bhk) 500U antihemophilic factor (recombinant), porcine sequence powder for injection vial with water for injection syringe, Shire Australia Pty Ltd , CON-359
Product name
OBIZUR susoctocog alfa (bhk) 500U antihemophilic factor (recombinant), porcine sequence powder for injection vial with water for injection syringe
Sponsor name
Shire Australia Pty Ltd
Batches
VM02492AD and VNM01481AF
Consent start
Consent no.
CON-359
Standard
Paragraph 7(2)(l) of Therapeutic Goods Order No. 69 '“ General Requirements for Labels for Medicines 2017
Non-compliance with standard
The products labels do not include the name and address of the current sponsor
of the goods.
Conditions imposed
The labels to which this consent applies are those previously approved for the
former Sponsor, Baxter Australia, and arrangements are in place with the former
Sponsor, Baxter Australia, for the prompt referral of any queries or complaints
concerning the products to Shire Australia Pty Ltd.
Therapeutic product type
Prescription medicines